ArticleEuropean radiology2026
Multifrequency magnetic resonance elastography for predicting pancreatic cancer aggressiveness and patient survival.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
objectivesTo evaluate the spatial heterogeneity of viscoelastic properties in pancreatic cancer, to correlate MR elastography (MRE) parameters with clinicopathological factors indicating tumor aggressiveness, and to identify risk factors for patient survival. MATERIALS AND
methodsThis retrospective study included 96 treatment-naive pancreatic cancer patients undergoing multifrequency MRE between September 2018 and May 2024. High-resolution parametric maps were generated to measure stiffness and fluidity in central, peripheral, and whole-tumor regions. Correlations between MRE parameters and tumor stage, grade, vascular and perineural invasion, regional lymphadenopathy, and distant metastasis were analyzed. Kaplan-Meier and Cox proportional hazards models were used to identify prognostic factors in patients with and without R0 resection, respectively.
resultsPeripheral fluidity of the tumor was higher than central fluidity (1.23 ± 0.25 vs 0.95 ± 0.19 rad, p < 0.001), whereas stiffness showed no zonal difference (p = 0.07). Tumor stiffness correlated positively with vascular invasion (ρ = 0.21, p = 0.04). Peripheral tumor fluidity correlated positively with tumor stage (ρ = 0.28, p = 0.007), perineural invasion (ρ = 0.31, p = 0.02), regional lymphadenopathy (ρ = 0.29, p = 0.005), and distant metastasis (ρ = 0.26, p = 0.01). In 48 R0-resected patients, higher peripheral fluidity was associated with shorter disease-free survival (DFS) (9.1 vs 19.4 months, p = 0.009) and was identified as an independent predictor of shorter DFS (hazard ratio, 2.15; 95% confidence interval: 1.03, 4.50; p = 0.04).
conclusionTumor biomechanical properties quantified by in vivo multifrequency MRE predict pancreatic cancer aggressiveness and patient survival. KEY POINTS: Question Pretreatment identification of aggressive pancreatic cancer remains challenging. Non-invasive imaging biomarkers are needed to stratify patient risk and optimize individualized treatment strategies. Findings Peripheral tumor fluidity quantified by multifrequency MRE correlates with pancreatic cancer aggressiveness and independently predicts DFS in patients with R0-resected pancreatic cancer. Clinical relevance MRE-derived peripheral fluidity provides a biophysical marker for pancreatic cancer aggressiveness. This facilitates risk stratification and identifying high-risk candidates for targeted neoadjuvant therapy.
Indexed as
Identifiers
42601528What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.